BCAX net incomeQ2 2026-$55.44M
BCAX net income was -$55.44M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$27.39M a year earlier. For the full fiscal 2025 it was -$137.95M, compared with -$68.00M in fiscal 2024.
Bicara Therapeutics Inc. (BCAX) financials
For the twelve months ended Jun 30, 2026, Bicara Therapeutics Inc. reported -$185.36M of net income.
- Net income, TTM
- -$185.36M
- Free cash flow, TTM
- -$135.25M
- Cash
- $96.60M
- Market cap
- $572.4M
FY2023FY2025
FY2023FY2025
BCAX revenue and earnings growth
BCAX EPSQ2 2026-$0.82
BCAX diluted EPS was -$0.82 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.50 a year earlier. For the full fiscal 2025 it was -$2.52.
BCAX free cash flowQ2 2026-$44.27M
BCAX free cash flow was -$44.27M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$25.59M a year earlier. For the full fiscal 2025 it was -$107.11M, compared with -$74.82M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | - | $63.60M | $30.60M |
| Selling, general and admin | $30.51M | $18.77M | $9.27M |
| Operating income | -$155.60M | -$82.39M | -$39.89M |
| Pre-tax income | -$137.73M | -$67.81M | -$51.98M |
| Income tax | $217.0K | $187.0K | $5.0K |
| Net income | -$137.95M | -$68.00M | -$51.98M |
| EPS, basic | -$2.52 | -$4.05 | -$89.61 |
| EPS, diluted | -$2.52 | -$4.05 | -$89.61 |
| Diluted shares | 54.68B | 16.81B | 580.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $96.69M | $489.71M | $230.44M |
| Short-term investments | $318.12M | $0 | - |
| Current assets | $422.05M | $502.53M | $231.07M |
| Total assets | $430.99M | $510.00M | $233.98M |
| Current liabilities | $28.95M | $17.99M | $15.09M |
| Total liabilities | $29.54M | $18.12M | $15.47M |
| Shareholders' equity | $401.45M | $491.88M | -$148.77M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$106.83M | -$74.75M | -$45.63M |
| Capital expenditures | $280.0K | $71.0K | $586.0K |
| Free cash flow | -$107.11M | -$74.82M | -$46.21M |
| Investing cash flow | -$318.45M | -$9.0K | -$586.0K |
| Financing cash flow | $32.26M | $334.03M | $272.50M |
| Stock-based compensation | $15.01M | $7.40M | $1.90M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | - | - | $33.00M | $24.80M | $34.30M | $19.90M | $15.90M | $15.80M | $12.00M | $10.50M | $6.90M |
| Selling, general and admin | $14.18M | $12.74M | $8.13M | $7.70M | $7.22M | $7.46M | $6.75M | $4.76M | $3.91M | $3.34M | $3.13M | $2.59M |
| Operating income | -$59.95M | -$60.24M | -$41.12M | -$40.68M | -$32.02M | -$41.79M | -$26.64M | -$20.63M | -$19.75M | -$15.37M | -$13.69M | -$9.53M |
| Pre-tax income | -$55.38M | -$56.16M | -$37.33M | -$36.29M | -$27.34M | -$36.77M | -$20.77M | -$17.48M | -$17.05M | -$12.51M | -$12.44M | -$22.84M |
| Income tax | $61.0K | $52.0K | $53.0K | $40.0K | $52.0K | $72.0K | $186.0K | $0 | $0 | $1.0K | $5.0K | $0 |
| Net income | -$55.44M | -$56.21M | -$37.39M | -$36.33M | -$27.39M | -$36.85M | -$20.96M | -$17.48M | -$17.05M | -$12.51M | -$12.44M | -$22.84M |
| EPS, basic | -$0.82 | -$0.93 | - | -$0.67 | -$0.50 | -$0.68 | - | -$1.60 | -$19.01 | -$18.94 | - | -$38.23 |
| EPS, diluted | -$0.82 | -$0.93 | - | -$0.67 | -$0.50 | -$0.68 | - | -$1.60 | -$19.01 | -$18.94 | - | -$38.23 |
| Diluted shares | 67.9M | 60.7M | - | 54.6M | 54.5M | 54.5M | - | 10.9M | 896,744 | 660,288 | - | 597,586 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $96.60M | $323.46M | $96.69M | $171.67M | $436.61M | $462.06M | $489.71M | $520.76M | $203.85M | $216.05M | $230.44M | $44.21M |
| Short-term investments | $400.66M | $216.29M | $318.12M | $118.49M | - | - | $0 | - | - | - | - | - |
| Current assets | $503.82M | $544.91M | $422.05M | $297.37M | $444.39M | $470.75M | $502.53M | $521.51M | - | - | $231.07M | - |
| Total assets | $512.24M | $553.60M | $430.99M | $424.69M | $453.59M | $478.08M | $510.00M | $524.17M | - | - | $233.98M | - |
| Current liabilities | $43.48M | $39.34M | $28.95M | $21.03M | $17.23M | $19.12M | $17.99M | $14.48M | - | - | $15.09M | - |
| Total liabilities | $43.48M | $39.64M | $29.54M | $21.91M | $18.39M | $19.12M | $18.12M | $14.62M | - | - | $15.47M | - |
| Shareholders' equity | $468.77M | $513.96M | $401.45M | $402.78M | $435.20M | $458.96M | $491.88M | $509.56M | -$174.78M | -$160.08M | -$148.77M | -$137.11M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.21M | -$37.51M | -$23.89M | -$29.25M | -$25.59M | -$28.11M | -$30.03M | -$17.22M | -$12.91M | -$14.59M | -$8.04M | - |
| Capital expenditures | $60.0K | $60.0K | $238.0K | $42.0K | $0 | $0 | $40.0K | $8.0K | $19.0K | $4.0K | $436.0K | - |
| Free cash flow | -$44.27M | -$37.57M | -$24.12M | -$29.29M | -$25.59M | -$28.11M | -$30.07M | -$17.23M | -$12.93M | -$14.59M | -$8.47M | - |
| Investing cash flow | -$184.99M | $100.94M | -$82.33M | -$236.12M | $0 | $0 | -$40.0K | -$8.0K | -$19.0K | $58.0K | -$436.0K | - |
| Financing cash flow | $2.33M | $163.34M | $31.23M | $436.0K | $135.0K | $460.0K | -$975.0K | $334.13M | $734.0K | $137.0K | $194.70M | - |
| Stock-based compensation | $8.24M | $5.86M | $4.45M | $3.61M | $3.49M | $3.45M | $3.18M | $2.03M | $1.04M | $1.15M | $765.0K | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.59 | 13.85 | 14.58 | 14.14 | 25.80 | 24.62 | 27.93 | 36.01 | - | - | 15.32 | - |
Source: XBRL data Bicara Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BCAX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BCAX | - | - | -$185.36M | - | $572.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
BCAX FAQ
5 questionsIs BCAX profitable?
No. Bicara Therapeutics Inc. reported a net loss of $185.36M for the twelve months ended Jun 30, 2026.How much cash and debt does BCAX have?
Bicara Therapeutics Inc. reported $96.60M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is BCAX free cash flow?
Bicara Therapeutics Inc. generated -$135.25M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$134.85M less capital expenditures.When did BCAX last report financial results?
The latest statements here come from Bicara Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this BCAX financial data come from?
Quantisnow builds these statements from the structured XBRL data Bicara Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.